I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Core Insights - Wei Fu, Chairman of the Board of I-Mab, intends to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) in open market transactions [1] - The Company has successfully executed its corporate strategy for 2024, with a focus on increasing shareholder value through portfolio prioritization [2] - I-Mab's lead clinical program is givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with data expected in early second half of 2025 [2] - The current cash runway for I-Mab extends into 2027 [2] Company Overview - I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment [3] - The Company has established operations in Rockville, Maryland, and Short Hills, New Jersey [3]